Myeloma
To study how safe and efficacious a type of CAR-T therapy works in patients with recurring blood cancer (relapsed/refractory Multiple Myeloma)
Who can joinAdults
Age18+ years
Kind of studyPhase 2: does it work?
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial CentreMumbaiDirections ↗
Registry summary (technical)
Phase I/II study of BCMA directed humanised CAR-T cell therapy (hBCMA) in patients with relapsed/refractory Multiple myeloma - NIL
Sponsor: Immunoadoptive Cell Therapy Private Limited (ImmunoACT)
CTRI/2025/01/079364 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 30 Mar 2026 · read by us 5 Nov 2026